(NASDAQ: BIAF) Bioaffinity Technologies's forecast annual revenue growth rate of -19.16% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 3.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,351.2%.
Bioaffinity Technologies's revenue in 2025 is $7,681,059.On average, 3 Wall Street analysts forecast BIAF's revenue for 2025 to be $5,891,993, with the lowest BIAF revenue forecast at $5,660,451, and the highest BIAF revenue forecast at $6,064,701.
In 2026, BIAF is forecast to generate $7,072,480 in revenue, with the lowest revenue forecast at $6,795,388 and the highest revenue forecast at $7,280,298.